Blocking central leukotrienes synthesis affects vasopressin release during sepsis.
Recent studies revealed that vasopressinergic neurons have a high content of cys-leukotriene C(4) (LTC(4)) synthase, a critical enzyme in cys-leukotriene synthesis that may play a role in regulating vasopressin secretion. This study investigates the role of this enzyme in arginine vasopressin (AVP) release during experimentally induced sepsis. Male Wistar rats received an i.c.v. injection of 3-[1-(p-chlorobenzyl)-5-(isopropyl)-3-tert-butylthioindol-2-yl]-2, 2-dimethylpropanoic acid (MK-886) (1.0 microg/kg), a leukotrienes (LTs) synthesis inhibitor, or vehicle, 1 h before cecal ligation and puncture (CLP) or sham operation. In one group of animals the survival rate was monitored for 3 days. In another group, the animals were decapitated at 0, 4, 6, 18 and 24 h after CLP or sham operation, and blood was collected for hematocrit, serum sodium and nitrate, plasma osmolality, protein and AVP determination. A third group was used for blood pressure measurements. The neurohypophysis was removed for quantification of AVP content, and the hypothalamus was dissected for LTC(4) synthase analysis by Western blot. Mortality after CLP was reduced by the central administration of MK-886. The increase in plasma AVP levels and hypothalamus LTC(4) synthase content in the initial phase of sepsis was blocked, whereas the decrease in neurohypophyseal AVP content was partially reversed. Also the blood pressure drop was abolished in this phase. The increase of serum nitric oxide and hematocrit was reduced, and the decrease in plasma protein and osmolality was not affected by the LTs blocker. In the final phase of sepsis, the plasma AVP level and the hypothalamic LTC(4) synthase content were at basal levels. The central administration of MK-886 increased the hypothalamic LTC(4) synthase content but did not alter the plasma and neurohypophysis AVP levels observed, or the blood pressure during this phase. These results suggest that the central LTs are involved in the vasopressin release observed during sepsis.
Athayde
L Antunes
LA
Departamento de Morfologia, Estomatologia e Fisiologia, Faculdade de Odontologia de Ribeirão Preto, Universidade de São Paulo, Avenida do Café s/n, Ribeirão Preto, SP, Brazil.
Oliveira-Pelegrin
G Ravanelli
GR
Nomizo
A
A
Faccioli
L H
LH
Rocha
M J Alves
MJ
D000818:Animals; D001127:Arginine Vasopressin / Q000097:blood / Q000378:metabolism*; D004195:Disease Models, Animal; D005982:Glutathione Transferase / Q000037:antagonists & inhibitors* / Q000378:metabolism; D006400:Hematocrit; D007022:Hypotension / Q000188:drug therapy / Q000201:enzymology / Q000503:physiopathology; D007031:Hypothalamus / Q000187:drug effects* / Q000378:metabolism*; D007211:Indoles / Q000494:pharmacology; D017997:Leukotriene C4 / Q000096:biosynthesis; D015289:Leukotrienes / Q000096:biosynthesis*; D016859:Lipoxygenase Inhibitors / Q000494:pharmacology; D008297:Male; D009569:Nitric Oxide / Q000097:blood; D010904:Pituitary Gland, Posterior / Q000187:drug effects / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D018805:Sepsis / Q000201:enzymology* / Q000503:physiopathology; D002722:Chlorobenzenes
D001127:Arginine Vasopressin; D005982:Glutathione Transferase; D007211:Indoles; D017997:Leukotriene C4; D015289:Leukotrienes; D016859:Lipoxygenase Inhibitors; D009569:Nitric Oxide; C060893:MK-886; D002722:Chlorobenzenes; C041116:leukotriene-C4 synthase